Intra-arterial Methylprednisolone After Endovascular Thrombectomy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT07516522

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07516522
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07516522. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-31 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intra-arterial Methylprednisolone After Endovascular Thrombectomy
Acronym
IMPACT-LVO
Condition
Ischemia Stroke
Condition
Thrombectomy
Condition
Large Vessel Occlusion
Intervention (Drug)
The methylprednisolone sodium succinate group
Intervention (Drug)
The placebo group
Lead sponsor
Tang-Du Hospital (class: other)

Record details

Record id
cardio:ct-nct07516522
Content hash
9386c2956ad061edf26abb243e6e00f440f940a151081558d4d730cf09484aa5